Madrigal Pharmaceuticals 2024 Corporate Presentation NASH

Madrigal Pharmaceuticals presents its clinical opportunity in NASH (nonalcoholic steatohepatitis) with resmetirom, a liver-directed THR-β agonist that achieved unprecedented Phase 3 results as the first therapy to achieve NASH resolution and fibrosis improvement. The company positions resmetirom as a first-to-market specialty therapy targeting patients with significant liver fibrosis.